UBS Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $60

Benzinga · 5d ago
UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $60.